Advisory Alpha’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Advisory Alpha’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-78,717	Closed	-$458K	–	272
2022 Q3	$458K	Hold	78,717	–	–	0.03%	167
2022 Q2	$470K	Hold	78,717	–	–	0.04%	164
2022 Q1	$368K	Hold	78,717	–	–	0.02%	200
2021 Q4	$195K	Sell	78,717 -25,000	-24%	-$61.2K	0.01%	256
2021 Q3	$306K	Buy	+103,717	New	+$282K	0.02%	201

Other funds holding CTIC

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Advisory Alpha's CTIC Position: Q4 2022 in Review

Advisory Alpha sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q4 2022, closing a stake of 78,717 shares — an estimated $458K sold.

Advisory Alpha first reported a position in CTIC in Q3 2021 and held it in 5 quarters. The position peaked at $470K in Q2 2022. 145 funds tracked by Wall St. Rank hold CTIC as of Q4 2022.

Advisory Alpha reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q4 2022 after selling out during the quarter.
Advisory Alpha sold 78,717 CTI BioPharma Corp. (DE) Common Stock shares in Q4 2022, an estimated $458K.
Advisory Alpha first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q3 2021 and held it in 5 quarters.
Advisory Alpha's CTI BioPharma Corp. (DE) Common Stock position peaked at $470K in Q2 2022.
145 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q4 2022.

Based on Advisory Alpha's 13F filing for Q4 2022, filed 30 Jan 2023.